DrugMonitor™ Anti-Cixutumumab Antibody (VS-1224-YC284) (CAT#: VS-1224-YC284)
Cixutumumab has been evaluated in clinical trials for treating lung cancer, malignant neoplasms, leukemia, mast-cell neoplasms, non-small-cell lung carcinoma, and adenocarcinoma of the prostate, known for its high affinity for the insulin-like growth factor-I receptor (IGF-IR) overexpressed in various tumors. The DrugMonitor™ Anti-Cixutumumab Antibody (VS-1224-YC284) is an anti-drug antibody (ADA) against Cixutumumab. This drug-based antibody is raised in mice immunized with the Cixutumumab. The anti-Cixutumumab antibody may be used in ELISA, pharmacokinetics (PK), and pharmacodynamics (PD) analyses, or serves as a reference standard in ADA assays. It also is an excellent tool for therapeutic drug monitoring, allowing to evaluate the drug efficacy and determine the drug concentration of the Cixutumumab in samples.
Specific Inquiry
Specifications
- Host Animal
- Mouse
- Specificity
- Cixutumumab
- Target
- Cixutumumab
- Immunogen
- Cixutumumab
- Type
- Mouse IgG
- Species Reactivity
- Human
- Purity
- >95%
- Purification
- Protein G
- Applications
- ELISA, PK/PD, ADA control
- Format
- Liquid
- Concentration
- Batch-dependent
- Buffer
- PBS, pH 7.4
- Preservative
- No preservatives
- Storage
- Store at 4°C for 1-2 weeks and at -20°C for 1 year. Avoid repeated freezing and thawing.
- Generic name
- Cixutumumab
- Related Disease
- lung cancer, malignant neoplasms, leukemia, mast-cell neoplasms, non-small-cell lung carcinoma, and adenocarcinoma of the prostate
Downloads
Download resources about recombinant antibody development and antibody engineering to boost your research.
See other products for "Cixutumumab"
Anti-Human IGF1 Receptor Recombinant Antibody (Cixutumumab)Recombinant monoclonal antibody to IGF1 Receptor. Cixutumumab is a monoclonal antibody for the treatment of solid tumors.
It is a fully human IgG1 monoclonal antibody directed against the human insulin-like growth factor-1 receptor (IGF-1R) with potential antineoplastic activity. Cixutumumab selectively binds to membrane-bound IGF-1R, thereby preventing the binding of the natural ligand IGF-1 and the subsequent activation of PI3K/AKT signaling pathway. Downregulation of the PI3K/AKT survival pathway may result in the induction of cancer cell apoptosis and may decrease cancer cellular proliferation. IGF-1R, a receptor tyrosine kinase of the insulin receptor superfamily overexpressed by many cancer cell types, stimulates cell proliferation, enables oncogenic transformation, and suppresses apoptosis; IGF-1R signaling has been implicated in tumorigenesis and metastasis.
Afuco™ Anti-IGF1R ADCC Recombinant Antibody, ADCC Enhanced (AFC-TAB-078)This product is an ADCC enhanced antibody produced by our Afuco™ platform. Recombinant monoclonal antibody to IGF1 Receptor. It is a monoclonal antibody for the treatment of solid tumors.
It is a fully human IgG1 monoclonal antibody directed against the human insulin-like growth factor-1 receptor (IGF-1R) with potential antineoplastic activity.
Customer Reviews and Q&As
There are currently no Customer reviews or questions for VS-1224-YC284. Click the button above to contact us or submit your feedback about this product.
Popular products with customers
Application: Neut, ELISA, IF, IP, FuncS, FC, ICC
Application: IF, IP, Neut, FuncS, ELISA, FC, ICC
Application: ELISA, IP, FC, FuncS, Neut, IF, IHC
Application: WB, IP, IF, FuncS, FC, Neut, ELISA
Application: ELISA, Neut, IF, IP, FC, FuncS
Application: FuncS, IF, Neut, ELISA, FC, IP, ICC
Application: FuncS, IF, Neut, ELISA, FC, IP, ICC
-1.png)
Application: IB, ELISA, FC, FuncS
Application: ELISA, IHC, FC, IP, IF, BL
Application: ELISA, PD, Activ, PK, Stim
-1.jpg)
Application: FC, FuncS, IA, IF, IP, IHC
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
Send Inquiry
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
